RE: SARS-CoV-2 infection protects against rechallenge in rhesus macaques21 May 2020 09:29
well good news again
nucleocapsid (N), has shown to be a target .. in which case you will have t cells that can activated by Immunobody ...
""We next evaluated SARS-CoV-2-specific humoral and cellular immune responses in these animals. All 9 macaques developed binding antibody responses to the SARS-CoV-2 Spike (S) protein by ELISA (Fig. 2A) and neutralizing antibody (NAb) responses using both a pseudovirus neutralization assay (10) (Fig. 2B) and a live virus neutralization assay (11, 12) (Fig. 2C). NAb titers of approximately 100 were observed in all animals on day 35 regardless of dose group (range 83-197 by the pseudovirus neutralization assay and 35-326 by the live virus neutralization assay). Antibody responses of multiple subclasses were observed against the receptor binding domain (RBD), the prefusion S ectodomain (S), and the nucleocapsid (N), and antibodies exhibited diverse effector functions, including antibody-dependent complement deposition (ADCD), antibody-dependent cellular phagocytosis (ADCP), antibody-dependent neutrophil phagocytosis (ADNP), and antibody-dependent NK cell degranulation (NK CD107a) and cytokine secretion (NK MIP1ß, NK IFN?) (13) (Fig. 2D). Cellular immune responses to pooled S peptides were observed in the majority of animals by IFN-? ELISPOT assays on day 35, with a trend toward lower responses in the lower dose groups (Fig. 2E). Intracellular cytokine staining assays demonstrated induction of both S-specific CD8+ and CD4+ T cell responses
Sign In
Follow the stocks
